A comparison of budesonide and mesalamine for active Crohn's disease

New England Journal of Medicine

Volumn 339, Issue 6, 1998, Pages 370-374

  Thomsen, Ole Østergaard ^a   Cortot, Antoine ^b   Jewell, Derek ^c   Wright, John P ^d   Winter, Trevor ^e   Veloso, Fernando Tavarela ^f   Vatn, Morten ^g   Persson, Tore ^h   Pettersson, Eva ^h  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d Kingsbury Hospital   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Clinical Research and Development   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; MESALAZINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUDESONIDE; CROHN DISEASE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; MALE; MESALAMINE; MIDDLE AGED; REMISSION INDUCTION;

EID: 0032491040     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808063390603     Document Type: Article

References (14)

1. Meyers S, Sachar DB. Medical management of Crohn's disease. Hepatogastroenterology 1990;37:42-55.
2. Summers RV, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77:847-69.
3. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990;4:407-14.
4. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41.
5. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331: 842-5.
6. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997; 41:209-14.
7. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993;104:1293-301.
8. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease: a 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987;22: 877-83.
9. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990;45:88-92.
10. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994;107:632-3.
11. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
12. Dupuy HJ. The Psychological General Well-Being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CD, Elinson J, eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing, 1984:170-83.
13. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980:144-9.
14. Schölmerich J, Jenss H, Hartmann F, et al. Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease. Can J Gastroenterol 1990;4:446-51.